Sobi Licenses Lacutamab from Innate Pharma to Advance Treatment of T-Cell Lymphoma
Swedish Orphan Biovitrum AB (Sobi®) and Innate Pharma SA have announced a strategic partnership aimed at enabling the initiation of the TELLOMAK-3 confirmatory Phase 3 trial of lacutamab in cutaneous T-cell lymphoma (CTCL). The study represents a significant milestone in advancing lacutamab toward a potential accelerated approval in Sézary syndrome, a subtype of CTCL.
As part of the agreement, Innate Pharma will lead the TELLOMAK-3 Phase 3 confirmatory study in CTCL, with the trial designed to support a potential accelerated approval application for lacutamab in Sézary syndrome. D...
